Diebold Nixdorf, Incorporated
DBD · NYSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.96 | -0.00 | -0.00 | 0.29 |
| FCF Yield | 8.14% | -15.13% | -27.14% | 4.47% |
| EV / EBITDA | 7.07 | 1.46 | -33.07 | 12.41 |
| Quality | ||||
| ROIC | -2.28% | 2.96% | -10.99% | 11.40% |
| Gross Margin | 24.53% | 23.30% | 21.88% | 26.72% |
| Cash Conversion Ratio | -10.29 | -0.19 | 0.66 | -1.56 |
| Growth | ||||
| Revenue 3-Year CAGR | 2.72% | -1.25% | -3.92% | -3.96% |
| Free Cash Flow Growth | 146.75% | 36.08% | -712.50% | 369.66% |
| Safety | ||||
| Net Debt / EBITDA | 2.24 | 0.44 | -19.35 | 6.72 |
| Interest Coverage | 1.17 | 0.35 | -0.64 | 0.70 |
| Efficiency | ||||
| Inventory Turnover | 5.36 | 4.89 | 4.60 | 5.26 |
| Cash Conversion Cycle | 66.02 | 77.75 | 61.40 | 34.96 |